Vancomycin (IV)

DRUG4 trials

Sponsors

Pfizer, University of Michigan, Todd C. Lee MD MPH FIDSA, Johns Hopkins University

Conditions

BacteremiaGram-Positive Bacterial InfectionsHealthy VolunteerHypersensitivity ReactionsPharmacokinetics and PharmacodynamicsS. Aureus BacteremiaS. Aureus Bloodstream InfectionStaphylococcus Aureus Bacteremia

Phase 1

Vancomycin Dose Optimization in Obesity

CompletedNCT06601257

University of MichiganPharmacokinetics and Pharmacodynamics

Start: 2025-04-01End: 2026-04-27Updated: 2026-05-22

Novel Biomarkers of Non-IgE Immediate Hypersensitivity Drug Reactions

RecruitingNCT07605806

Johns Hopkins UniversityHealthy Volunteer, Hypersensitivity Reactions, Vancomycin

Start: 2026-05-21End: 2027-06-30Target: 25Updated: 2026-08-05

Phase 3

Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections

TerminatedNCT00108433

PfizerBacteremia, Gram-Positive Bacterial Infections

Start: 2005-09-30End: 2006-09-30Updated: 2012-08-07

Phase 4

Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

RecruitingNCT06637332

Todd C. Lee MD MPH FIDSAS. Aureus Bacteremia, S. Aureus Bloodstream Infection, Staphylococcus Aureus Bacteremia +2

Start: 2024-11-14End: 2029-11-01Target: 300Updated: 2026-09-09